Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements, a filing shows. The move is unusual as it comes more than a year before the drug, orforglipron, is expected to be launched. Most drugmakers include such inventories, or assets, in their financial statements to show how much drug product has been manufactured right before approval.
